Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals [0.03%]
抗体药物偶联物（ADC）：当前和未来的生物制药产品
Ruili Wang,Baohui Hu,Ziyu Pan et al.
Ruili Wang et al.
Antibody-drug conjugates (ADCs) represent a novel class of biopharmaceuticals comprising monoclonal antibodies covalently conjugated to cytotoxic agents via engineered chemical linkers. This combination enables targeted delivery of cytotoxi...
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs [0.03%]
靶向降解细胞外蛋白：最新进展及降解剂设计多样性
M A A Mamun,Anush G Bakunts,Alexander L Chernorudskiy
M A A Mamun
Selective elimination of proteins associated with the pathogenesis of diseases is an emerging therapeutic modality with distinct advantages over traditional inhibitor-based approaches. This strategy, called targeted protein degradation (TPD...
A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma [0.03%]
HH2853治疗复发/难治外周T细胞淋巴瘤的多中心、开放性单组Ⅰb期临床试验
Huangming Hong,Zegeng Chen,Mingzhi Zhang et al.
Huangming Hong et al.
Background: Peripheral T-cell lymphoma (PTCL) is an aggressive malignancy with limited treatment options and poor prognosis, particularly for relapsed or refractory (r/r) patients. HH2853, a novel dual inhibitor of EZH1/2...
Correction: The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications [0.03%]
关于cGAS-STMG通路在癌症免疫中的作用：机制、挑战及治疗意义的更正通知
Mengzhou Shen,Xianjie Jiang,Qiu Peng et al.
Mengzhou Shen et al.
Published Erratum
Journal of hematology & oncology. 2025 Apr 27;18(1):49. DOI:10.1186/s13045-025-01706-1 2025
PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma [0.03%]
新诊断原发中枢神经系统淋巴瘤患者的PFS24预后里程碑事件
Vanja Zeremski,Tobias R Haage,Hanno M Witte et al.
Vanja Zeremski et al.
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation has significantly improved overall survival (OS) in primary central nervous system lymphoma (PCNSL). However, early identification of long-term survivors ...
Multicenter Study
Journal of hematology & oncology. 2025 Apr 24;18(1):48. DOI:10.1186/s13045-025-01700-7 2025
Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease [0.03%]
空间成像解锁了绘制多发性骨髓瘤和髓外病变潜力的功能
Vanessa Desantis,Alessandro Andriano,Tim Düking et al.
Vanessa Desantis et al.
Extramedullary disease (EMD) in multiple myeloma (MM) represents a significant clinical challenge, with a limited understanding of the spatial architecture and its pathobiological impact. To address this unmet need, we examined 10 matched s...
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting [0.03%]
2024年ASH年会关于CD20×CD3双特异性抗体治疗大B细胞淋巴瘤的最新进展
V Tomarchio,L Rigacci,O Annibali
V Tomarchio
Bispecific antibodies (BsAbs) represent an innovative class of off-the-shelf T-cell redirecting agents and are considered among the most promising immunotherapeutic strategies for the treatment of lymphoma. Notably, anti-CD20 × CD3 BsAbs h...
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma [0.03%]
胰腺导管腺癌患者采用液态活检技术检测KRAS突变
Mahmoud Yousef,Abdelrahman Yousef,Mark W Hurd et al.
Mahmoud Yousef et al.
The clinical utility of liquid biopsy (LB) for pancreatic ductal adenocarcinoma (PDAC) remain understudied. Our single-institution cohort of 311 PDAC patients with non-tumor tissues informed LB found 81.2% positivity (N = 186) in metastatic...
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy [0.03%]
基于纳米材料的原位疫苗接种疗法：肿瘤免疫治疗的新前沿
Naimeng Liu,Xiangyu Wang,Zhongzhao Wang et al.
Naimeng Liu et al.
In situ vaccination (ISV) has emerged as a promising strategy in cancer immunotherapy, offering a targeted approach that uses the tumor microenvironment (TME) to stimulate an immune response directly at the tumor site. This method minimizes...
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer [0.03%]
复制型RNA疫苗：设计、递送及在传染病和癌症中的免疫原性
Lirui Tang,Haiying Que,Yuquan Wei et al.
Lirui Tang et al.
Replicon RNA (RepRNA) represents a cutting-edge technology in the field of vaccinology, fundamentally transforming vaccine design and development. This innovative approach facilitates the induction of robust immune responses against a range...